Healthcare Industry News: electrotherapy
News Release - August 14, 2006
Zynex Medical Adds Six Industry Veterans to Sales ForceLITTLETON, Colo.--(HSMN NewsFeed)--Aug. 14, 2006--Zynex Medical Holdings, Inc. (OTCBB: ZYNX ) has hired six new sales representatives, bringing the total number of reps to 26. As previously announced, ten sales reps were hired last month. All 16 new sales professionals are highly experienced in electrotherapy and medical technology sales. Their addition to the Zynex team is expected to significantly broaden the Company's potential client base.
The Company's impetus in more than doubling its sales force is to increase interest in its fully developed, FDA-cleared standard electrotherapy medical products.
"With the hiring of additional salespeople, we have taken yet another step toward increasing our revenues and market penetration in an already successful Zynex business," said Thomas Sandgaard, President and Chief Executive Officer. "We will continue to execute our strategy, add more sales representatives and anticipate the expanded sales force to contribute significantly to the overall growth of our Company."
About Zynex Medical Holdings, Inc.
Zynex Medical Holdings, Inc. (founded in 1996) engineers, manufactures, markets and sells its own design of electrotherapy medical devices in two distinct markets: standard digital electrotherapy products for pain relief and pain management; and the NeuroMove(TM) for stroke and spinal cord injury (SCI) rehabilitation. Zynex's product lines are fully developed, FDA-cleared, commercially sold, and have been developed to uphold the Company's mission of improving the quality of life for patients suffering from impaired mobility due to stroke, spinal cord injury, or debilitating and chronic pain.
Safe Harbor Statement
Certain statements in this release are "forward-looking" and as such are subject to numerous risks and uncertainties. Actual results may vary significantly from the results expressed or implied in such statements. Factors that could cause actual results to materially differ from forward-looking statements include, but are not limited to, risks and delays associated with product development, risk of market acceptance of products, technology or product obsolescence, competitive risks, reliance on manufacturing partners, dependence on reimbursement from insurance companies, additional capital needs and other risks described in our Form 10-KSB for the year ended December 31, 2005.
Source: Zynex Medical Holdings
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.